China NMPA Drug Inspection - Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd.

On September 11, 2020, the Gansu Provincial Drug Administration issued a formal drug quality announcement revealing that 12 batches of pharmaceuticals from 11 companies failed to meet established quality standards. A prominent entity identified in the report is Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd. The findings resulted from sampling inspections conducted by various testing bodies, including the Jiayuguan Municipal Food, Drug and Medical Device Testing Center. The primary violations involved failures in physical properties, identification tests for authenticity and safety, and content determination, which evaluates the concentration of active ingredients. Operating under the regulatory framework of the National Medical Products Administration (NMPA), the provincial authorities have initiated strict enforcement actions. These measures include the immediate sealing and seizure of substandard products and the commencement of formal investigations into the involved companies. Regulatory bodies are required to oversee the rectification process, ensuring that the manufacturers identify the root causes of these failures and implement corrective measures to mitigate safety risks. The administration has committed to publishing the final results of these investigations within three months, maintaining transparency in their oversight of drug safety and public health protection.